Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy
| Autor: | Maurizio Vecchi, Chiara Ricci, Francesca Ferretti, Luca Pastorelli, Claudio Camillo Cortelezzi, Giovanni Maconi, Simone Saibeni, Francesco Conforti, A. Indriolo, Sandro Ardizzone, M. Parravicini, M. Bosani, Stefania Carmagnola, Valentina Casini, Piercarlo Sarzi-Puttini, Stefano Mazza, Marco Vincenzo Lenti, Paola Cosimo, M.C. Monico, Cristina Bezzio, Andrea Cassinotti, Flavio Caprioli, Anna Maria Carvalhas Gabrielli, Antonio Di Sabatino |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Population Disease Inflammatory bowel disease SARS‐CoV‐2 Biological Factors Young Adult COVID‐19 Internal medicine medicine Humans Cumulative incidence Risk factor education Child Aged Retrospective Studies education.field_of_study Hepatology business.industry SARS-CoV-2 Incidence (epidemiology) Incidence Infant Newborn Gastroenterology COVID-19 Infant Middle Aged medicine.disease Colitis Inflammatory Bowel Diseases Biological Therapy Child Preschool Cohort Observational study Female business Biologic therapy |
| Zdroj: | Journal of Gastroenterology and Hepatology |
| ISSN: | 1440-1746 |
| Popis: | Background and Aim Since the outbreak of COVID‐19, concerns have been raised as to whether inflammatory bowel disease (IBD) patients under biologic therapy may be more susceptible to the disease. This study aimed to determine the incidence and outcomes of COVID‐19 in a large cohort of IBD patients on biologic therapy. Methods This observational retrospective multicenter study collected data about COVID‐19 in IBD patients on biologic therapy in Italy, between February and May 2020. The main end‐points were (i) to assess both the cumulative incidence and clinical outcome of COVID‐19, according to different biologic agents and (ii) to compare them with the general population and a cohort IBD patients undergoing non‐biologic therapies. Results Among 1816 IBD patients, the cumulative incidence of COVID‐19 was 3.9 per 1000 (7/1816) with a 57% hospitalization rate and a 29% case‐fatality rate. The class of biologic agents was the only risk factor of developing COVID‐19 (P = 0.01). Non‐gut selective agents were associated with a lower incidence of COVID‐19 cases, related symptoms, and hospitalization (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text